Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Karah Smith

Physician Assistant Dalton, GA Physician Assistant

NPI 1285622746 CMS profile 10561449

1114 Professional Blvd, Dalton, GA 30720

Open in the dashboard

General payments

$2,153

127 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Karah Smith of Dalton, GA is reported in the CMS Open Payments database as having received $2,153 across 127 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $55 3
2024 General $790 44
2023 General $747 46
2022 General $544 33
2021 General $17 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karah Smith
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Karah Smith were reported at $55. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Karah Smith Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $17 $132 $37–$438 $132
2022 $544 $155 $48–$522 $149
2023 $747 $167 $52–$557 $160
2024 $790 $178 $55–$600 $164
2025 $55 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $346 24 payments
  2. AbbVie, Inc. $342 19 payments
  3. Pfizer Inc. $274 17 payments
  4. Novo Nordisk Inc $229 13 payments
  5. Abbott Laboratories $120 7 payments
  6. Amgen Inc. $100 5 payments
  7. Sanofi-Aventis U.S. LLC $92 5 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $92 5 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $72 4 payments
  10. Medtronic, Inc. $59 3 payments
  11. Other $426 25 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,153 127 payments
Products named General payments · program years 2021–2025
  1. MOUNJARO $253 18 payments
  2. RYBELSUS $194 11 payments
  3. VRAYLAR $190 8 payments
  4. NURTEC ODT $164 11 payments
  5. Ozempic $159 9 payments
  6. ELIQUIS $139 9 payments
  7. PREVNAR 20 $110 6 payments
  8. UBRELVY $108 7 payments
  9. ABRYSVO $92 5 payments
  10. COMIRNATY $92 5 payments
  11. Other $1,467 88 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 136 drugs

Part D claims

8,128

Median for Physician Assistant: 241

Drug cost

$557,284

Median for Physician Assistant: $4,110

Branded share of claims

17.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 96 $84,148
Mounjaro Tirzepatide Brand 64 $70,213
Ozempic Semaglutide Brand 62 $61,741
Trulicity Dulaglutide Brand 27 $35,577
Januvia Sitagliptin Phosphate Brand 35 $32,118
Eliquis Apixaban Brand 43 $31,876
Farxiga Dapagliflozin Propanediol Brand 36 $29,728
Rybelsus Semaglutide Brand 12 $20,500
Janumet Sitagliptin Phos/Metformin Hcl Brand 20 $18,593
Tresiba Flextouch U-200 Insulin Degludec Brand 11 $17,407

The 10 drugs with the highest cost, of 136 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 78 billing codes

Paid by Medicare

$121,518

Of which drugs: $16,435

Medicare patients

404

Average age 74

Services billed

7,083

314 women, 90 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 41%
Diabetes 33%
Ischemic heart disease 27%
Chronic kidney disease 23%
Depression 22%
Osteoporosis 20%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 42 42 $11,957
Vaccine for influenza for injection into muscle 90662 Office 44 45 $3,632
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 65 320 $234
Injection, methylprednisolone acetate, 20 mg J1020 Office 44 91 $149
Injection, ketorolac tromethamine, per 15 mg J1885 Office 39 176 $76
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 31 69 $50
Injection, ceftriaxone sodium, per 250 mg J0696 Office 36 154 $43
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 105 524 $36
Injection, methylprednisolone acetate, 1 mg J1010 Office 12 21 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $87
$87 64 —
RYBELSUS
  • Novo Nordisk Inc $65
$65 12 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $53
$53 — —
ZEPBOUND
  • Lilly USA, LLC $50
$50 — —
Ozempic
  • Novo Nordisk Inc $44
$44 62 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

127 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record